Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Cash & Equivalents (2022 - 2025)

TriSalus Life Sciences' Cash & Equivalents history spans 4 years, with the latest figure at $20.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 139.75% year-over-year to $20.4 million; the TTM value through Dec 2025 reached $20.4 million, up 139.75%, while the annual FY2025 figure was $20.4 million, 139.75% up from the prior year.
  • Cash & Equivalents reached $20.4 million in Q4 2025 per TLSIW's latest filing, down from $22.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $26.5 million in Q2 2025 to a low of $50930.0 in Q1 2022.
  • Average Cash & Equivalents over 4 years is $11.8 million, with a median of $11.5 million recorded in 2023.
  • The largest YoY upside for Cash & Equivalents was 2802.09% in 2024 against a maximum downside of 47.21% in 2024.
  • A 4-year view of Cash & Equivalents shows it stood at $9.4 million in 2022, then grew by 25.1% to $11.8 million in 2023, then fell by 27.61% to $8.5 million in 2024, then skyrocketed by 139.75% to $20.4 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Cash & Equivalents are $20.4 million (Q4 2025), $22.7 million (Q3 2025), and $26.5 million (Q2 2025).